Literature DB >> 20130057

Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus.

Mauro Pistello1, Francesca Bonci, Elisa Zabogli, Francesca Conti, Giulia Freer, Fabrizio Maggi, Mario Stevenson, Mauro Bendinelli.   

Abstract

The envelope (Env) glycoproteins of HIV and other lentiviruses possess neutralization and other protective epitopes, yet all attempts to induce protective immunity using Env as the only immunogen have either failed or afforded minimal levels of protection. In a novel prime-boost approach, specific-pathogen-free cats were primed with a plasmid expressing Env of feline immunodeficiency virus (FIV) and feline granulocyte-macrophage colony-stimulating factor and then boosted with their own T lymphocytes transduced ex vivo to produce the same Env and interleukin 15 (3 x 10(6) to 10 x 10(6) viable cells/cat). After the boost, the vaccinees developed elevated immune responses, including virus-neutralizing antibodies (NA). Challenge with an ex vivo preparation of FIV readily infected all eight control cats (four mock vaccinated and four naïve) and produced a marked decline in the proportion of peripheral CD4 T cells. In contrast, five of seven vaccinees showed little or no traces of infection, and the remaining two had reduced viral loads and underwent no changes in proportions of CD4 T cells. Interestingly, the viral loads of the vaccinees were inversely correlated to the titers of NA. The findings support the concept that Env is a valuable immunogen but needs to be administered in a way that permits the expression of its full protective potential.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20130057      PMCID: PMC2849480          DOI: 10.1128/JVI.02638-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.

Authors:  Margaret J Hosie; Dieter Klein; James M Binley; Thomas H Dunsford; Oswald Jarrett; James C Neil; Elzbieta Knapp; Simone Giannecchini; Donatella Matteucci; Mauro Bendinelli; James A Hoxie; Brian J Willett
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

2.  Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters.

Authors:  Florencia Pereyra; Sarah Palmer; Toshiyuki Miura; Brian L Block; Ann Wiegand; Alissa C Rothchild; Brett Baker; Rachel Rosenberg; Emily Cutrell; Michael S Seaman; John M Coffin; Bruce D Walker
Journal:  J Infect Dis       Date:  2009-09-15       Impact factor: 5.226

Review 3.  FIV infection of the domestic cat: an animal model for AIDS.

Authors:  B J Willett; J N Flynn; M J Hosie
Journal:  Immunol Today       Date:  1997-04

Review 4.  CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection?

Authors:  Scott A Brown; Julia L Hurwitz; Xiaoyan Zhan; Peter C Doherty; Karen S Slobod
Journal:  Curr Drug Targets Infect Disord       Date:  2005-06

Review 5.  Lessons from the cat: development of vaccines against lentiviruses.

Authors:  Stephen P Dunham
Journal:  Vet Immunol Immunopathol       Date:  2006-05-05       Impact factor: 2.046

Review 6.  Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine.

Authors:  Janet K Yamamoto; Ruiyu Pu; Eiji Sato; Tsutomu Hohdatsu
Journal:  AIDS       Date:  2007-03-12       Impact factor: 4.177

7.  Sequences within the gag gene of feline immunodeficiency virus (FIV) are important for efficient RNA encapsidation.

Authors:  Matthew T Browning; Farah Mustafa; Russell D Schmidt; Kathy A Lew; Tahir A Rizvi
Journal:  Virus Res       Date:  2003-06       Impact factor: 3.303

Review 8.  Passive immunization as tool to identify protective HIV-1 Env epitopes.

Authors:  Victor G Kramer; Nagadenahalli B Siddappa; Ruth M Ruprecht
Journal:  Curr HIV Res       Date:  2007-11       Impact factor: 1.581

9.  Frequency of long-term nonprogressors in HIV-1 seroconverters From Rakai Uganda.

Authors:  Oliver Laeyendecker; Andrew D Redd; Tom Lutalo; Ronald H Gray; Maria Wawer; Victor Ssempijja; Jordyn Gamiel; John Baptist Bwanika; Fred Makumbi; Fred Nalugoda; Pius Opendi; Godfrey Kigozi; Anthony Ndyanabo; Boaz Iga; Noah Kiwanuka; Nelson Sewankambo; Steven J Reynolds; David Serwadda; Thomas C Quinn
Journal:  J Acquir Immune Defic Syndr       Date:  2009-11-01       Impact factor: 3.731

10.  Streamlined design of a self-inactivating feline immunodeficiency virus vector for transducing ex vivo dendritic cells and T lymphocytes.

Authors:  Mauro Pistello; Laura Vannucci; Alessia Ravani; Francesca Bonci; Flavia Chiuppesi; Barbara del Santo; Giulia Freer; Mauro Bendinelli
Journal:  Genet Vaccines Ther       Date:  2007-09-19
View more
  6 in total

1.  Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies.

Authors:  James K Coleman; Ruiyu Pu; Marcus M Martin; Ezra N Noon-Song; Raphael Zwijnenberg; Janet K Yamamoto
Journal:  Vaccine       Date:  2013-06-22       Impact factor: 3.641

Review 2.  Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine.

Authors:  J R Abbott; M P Sanou; J K Coleman; J K Yamamoto
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

3.  Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein.

Authors:  Michele Celestino; Arianna Calistri; Claudia Del Vecchio; Cristiano Salata; Flavia Chiuppesi; Mauro Pistello; Alessandra Borsetti; Giorgio Palù; Cristina Parolin
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

4.  An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection.

Authors:  Alek M Aranyos; Shannon R Roff; Ruiyu Pu; Jennifer L Owen; James K Coleman; Janet K Yamamoto
Journal:  Vaccine       Date:  2016-01-21       Impact factor: 3.641

5.  Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccine.

Authors:  Paweł M Bęczkowski; Matthew Harris; Navapon Techakriengkrai; Julia A Beatty; Brian J Willett; Margaret J Hosie
Journal:  Vaccine       Date:  2015-01-19       Impact factor: 3.641

Review 6.  Developments in Viral Vector-Based Vaccines.

Authors:  Takehiro Ura; Kenji Okuda; Masaru Shimada
Journal:  Vaccines (Basel)       Date:  2014-07-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.